RxDoctor Payments Data

Rebecca Allen Legault

Psychiatric/Mental Health · Granger, INNPI 1104892371

Payments from drug & device makers

$206in general payments, 2019–2025

Across 7 payments — averaging $29.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$104
  • Abbott$21
  • Biogen$19
  • Urgo Medical North America, LLC$18
  • Lilly USA, LLC$17
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$15
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$206100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$206 in reported general payments places this provider in the 25th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$123,544
Medicare patients
288
Services billed
1,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Escitalopram Oxalate1,596$23,808
RexultiBrexpiprazole30$17,481
NuedextaDextromethorphan Hbr/Quinidine21$12,798
Lorazepam671$9,742
Divalproex Sodium188$9,407
Risperidone ErRisperidone Microspheres18$7,072
Quetiapine Fumarate255$6,134
Olanzapine136$5,510
Breo ElliptaFluticasone/Vilanterol12$5,192
Duloxetine Hcl155$4,256
Clozapine81$4,112
Sertraline Hcl373$3,649
Mirtazapine169$3,222
Clonazepam174$3,085
Haloperidol89$3,004

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$17$5,510136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Granger

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →